Table 1.
Patient characteristics.
| Patient | Age (years) | Sex (M/F) | Müller scorea | SPT peanut | Subjective effective dose (ED) (mg) | Objective ED (mg) | Total IgE (IU/mL) | CAP peanut (kU/L) | Percentage basophils (% total) |
|---|---|---|---|---|---|---|---|---|---|
| N01 | 41 | F | 2 | 3+ | 10 | – | 238 | 1.7 | 0.35 |
| N02 | 37 | M | 4 | 3+ | 0.1 | 300 | 1,482 | 44 | 0.63 |
| N03 | 45 | M | 2 | 4+ | 100 | – | 101 | 1.8 | 0.40 |
| N04 | 50 | F | 3 | 4+ | 10 | 10 | 1,537 | 12 | 0.38 |
| N05 | 35 | F | 4 | 4+ | 0.1 | – | 535 | 85 | 0.62 |
| N06 | 27 | F | 2 | 4+ | 4 | 40 | 3,786 | 12.8 | 0.26 |
| N07 | 42 | M | 3 | 5+ | Not known | 300 | 599 | 42.7 | 0.30 |
| N08 | 24 | M | 1 | 4+ | 100 | >3,000 | 2,054 | 1.9 | 0.20 |
| N09 | 24 | F | 3 | 3+ | Not known | >3,000 | 1,062 | 1 | 0.34 |
| N10 | 18 | F | 3 | 4+ | 300 | 1,000 | 5,823 | >100 | 0.40 |
| N11 | 32 | F | 2 | 4+ | 10 | 3,000 | 3,941 | No data | 0.40 |
| N12 | 27 | M | 3 | 5+ | 0.1 | 1,000 | 59,272 | 66 | 0.41 |
| N13 | 25 | M | 1 | 3+ | 10 | – | 2,302 | 11.2 | 0.53 |
| N14 | 26 | F | 2 | 4+ | 0.1 | 100 | 3,287 | 9.7 | 0.53 |
| N15 | 34 | F | 2 | 4+ | 40 | 12,000 | 1,347 | 1.55 | 0.25 |
Age, sex, Müller score, SPT, subjective and objective ED as established by double-blind placebo-controlled food challenge (DBPCFC), total and peanut-specific IgE, and average basophil count per subject.
aMüller score 0: symptoms oral cavity, 1: symptoms of the skins and mucous membranes, 2: gastro-intestinal symptoms, 3: respiratory symptoms, 4: cardiovascular symptoms.
Skin prick test (mm), diameter of 3 mm (3+) is considered positive. All patients underwent a DBPCFC, subjective and objective EDs are displayed in mg.